Jonathan E. Rosenberg, B.S. M.D.

Instructor, Department of Medicine, Harvard Medical School

Physician, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Contact Info

Jonathan Rosenberg
Dana-Farber Cancer Institute
44 Binney Street
Boston, MA, 02115
Mailstop: D1230K
Phone not available.
jonathan_rosenberg@dfci.harvard.edu

Assistant

Not Available.

DF/HCC Program Affiliation

Research Abstract

Publications

• Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ,.Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.Ann Oncol 2008 May;
  18272914
• Rosenberg JE.Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.Expert Rev Anticancer Ther 2007 Dec;7(12):1729-36.
  18062747
• Motzer RJ, Michaelson MD, Rosenberg J, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Wilding G.Sunitinib efficacy against advanced renal cell carcinoma.J Urol 2007 Nov;178(5):1883-7.
  17868732
• Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ.Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or m
  17577218
• Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ.Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer.BJU Int 2007 Mar;99(3):519-24.
  17407512
• Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ.A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabep
  16329138
• Rosenberg JE, Carroll PR, Small EJ.Update on chemotherapy for advanced bladder cancer.J Urol 2005 Jul;174(1):14-20.
  15947569
• Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ.A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell
  15812833
• Rosenberg JE, Small EJ.Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?.Clin Prostate Cancer 2004 Sep;3(2):122-4.
  15479496